Clinical Trial

A Phase 2A Clinical Trial to Assess the Safety and Tolerability of ERX1000 in Men and Women for the Treatment of Obesity.

Name: A Phase 2A Clinical Trial to Assess the Safety and Tolerability of ERX1000 in Men and Women for the Treatment of Obesity. — clinical trial record (NCT07570758)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

The primary objective is to assess the safety and tolerability of oral dose ERX1000 in obese subjects.

Protocol Amendment History 2 changes

critical Recruitment opened 2026-06-23

notable Trial sites expanded: 0 -> 3 locations 2026-06-23

Trial Details

NCT Number	NCT07570758
Lead Sponsor	ERX Pharmaceuticals
Conditions	Obesity & Overweight
Enrollment	80 participants
Start Date	2026-05-28
Primary Completion	2027-05 (estimated)
Study Completion	2027-05 (estimated)
Updated on ClinicalTrials.gov	2026-06-22